Literature DB >> 24522556

[Acute mountain sickness : How can it be treated and how can it be avoided?].

R Fischer1.   

Abstract

Due to the decreasing partial pressure of oxygen, high altitude sickness can occur at heights over 2,500 m. This can be best avoided by slow adaptation to the altitude (acclimatization). In this way the organism adapts to the chronic hyperventilation and in the further process the oxygen content is normalized by an increase in erythrocytes. The commonest form of high altitude sickness is acute mountain sickness which is characterized by the leading symptom of headache. When additional signs of ataxia occur there is an acute danger of edema which is associated with a high mortality. Stress dyspnea, coughing and rasping breathing noises also occur by the potentially fatal high altitude pulmonary edema. All forms of high altitude sickness can be countered by a rapid descent to a height of at least 500 m. In acute mountain sickness acetazolamide can be administered (2 × 250 mg), for high altitude cerebral edema dexamethasone (3 × 4-8 mg) and for high altitude pulmonary edema nifedipine (initially 10 mg then 20 mg retard).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24522556     DOI: 10.1007/s00108-013-3368-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate.

Authors:  Michael Schneider; Dirke Bernasch; Jorn Weymann; Rolf Holle; Peter Bartsch
Journal:  Med Sci Sports Exerc       Date:  2002-12       Impact factor: 5.411

Review 2.  Treatment of high altitude diseases without drugs.

Authors:  P Bärtsch
Journal:  Int J Sports Med       Date:  1992-10       Impact factor: 3.118

Review 3.  Clinical practice: Acute high-altitude illnesses.

Authors:  Peter Bärtsch; Erik R Swenson
Journal:  N Engl J Med       Date:  2013-06-13       Impact factor: 91.245

4.  Hemosiderin deposition in the brain as footprint of high-altitude cerebral edema.

Authors:  Kai Schommer; Kai Kallenberg; Kira Lutz; Peter Bärtsch; Michael Knauth
Journal:  Neurology       Date:  2013-10-09       Impact factor: 9.910

5.  Reduced incidence and severity of acute mountain sickness in Qinghai-Tibet railroad construction workers after repeated 7-month exposures despite 5-month low altitude periods.

Authors:  Tian Yi Wu; Shou Quan Ding; Jin Liang Liu; Man Tang Yu; Jian Hou Jia; Jun Qing Duan; Zuo Chuan Chai; Rui Chen Dai; Sheng Lin Zhang; Bao Zhu Liang; Ji Zhui Zhao; De Tang Qi; Yong Fu Sun; Bengt Kayser
Journal:  High Alt Med Biol       Date:  2009       Impact factor: 1.981

6.  Early fluid retention and severe acute mountain sickness.

Authors:  Jack A Loeppky; Milton V Icenogle; Damon Maes; Katrina Riboni; Helmut Hinghofer-Szalkay; Robert C Roach
Journal:  J Appl Physiol (1985)       Date:  2004-10-22

7.  Prevention of high-altitude pulmonary edema by nifedipine.

Authors:  P Bärtsch; M Maggiorini; M Ritter; C Noti; P Vock; O Oelz
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

Review 8.  Gene expression in chronic high altitude diseases.

Authors:  Fabiola León-Velarde; Olga Mejía
Journal:  High Alt Med Biol       Date:  2008       Impact factor: 1.981

Review 9.  From mountain to bedside: understanding the clinical relevance of human acclimatisation to high-altitude hypoxia.

Authors:  D Martin; J Windsor
Journal:  Postgrad Med J       Date:  2008-12       Impact factor: 2.401

Review 10.  High-altitude illness.

Authors:  Buddha Basnyat; David R Murdoch
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.